COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01374776
Recruitment Status : Unknown
Verified December 2013 by University of Zurich.
Recruitment status was:  Recruiting
First Posted : June 16, 2011
Last Update Posted : December 13, 2013
Information provided by (Responsible Party):
University of Zurich

Brief Summary:

Effect of intravenous iron substitution (iron carboxymaltose (Ferinject®), total dose 15 mg/ kg (maximal dose: 1000mg) in 250 ml 0.9 % NaCl; intravenous infusion in 20 min)in non-anemic premenopausal women with iron deficiency on

Primary objective:

- Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of the lower leg muscle)

Secondary objectives:

  • Maximal oxygen uptake during a graded cycling exercise test and time to exhaustion at submaximal power during a constant-load cycling exercise test
  • Plantarflexor muscle fatiguability as assessed by isokinetic dynamometry
  • Trial with medicinal product

Condition or disease Intervention/treatment Phase
Non Anemic Patients With Iron Deficiency (Low Ferritin Value) Drug: Double blind, randomized, placebo controlled inter Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : February 2013
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron

Intervention Details:
  • Drug: Double blind, randomized, placebo controlled inter
    The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.

Primary Outcome Measures :
  1. Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of the lower leg muscle) [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria: INCLUSION CRITERIA

  • Healthy female subjects, Age > 18 years, premenopausal, regularly menstruating
  • BMI 18-25 kg/m2.
  • Serum ferritin level < 15ug/ml
  • Recreationally active with = 1.5 h/w structured activity
  • Adequate contraception during the study period
  • Informed consent

Exclusion criteria: EXCLUSION CRITERIA

  • Anemia with Hb level < 120 g/l
  • Known hypersensitivity to iron carboxymaltose, iron sucrose or iron sulfate
  • Intake of iron preparations (also multivitamins containing iron) during the last 8 weeks before the start of the trial protocol
  • Pregnancy or lactation
  • Any cardiovascular or pulmonary disease
  • Any orthopaedic or rheumatologic disease which affects exercise performance
  • Presence of muscle disease
  • Acute or chronic infection/inflammation or malignancy
  • Known mental disorders (e.g. depression)
  • Intake of concurrent medication, except oral contraceptives
  • CRP > 10 mg/l
  • TSH out of normal range
  • Elevated CK (> 167 U/l)
  • Any concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.
  • Participation in any other therapeutic trial within the previous month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01374776

Layout table for location contacts
Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Layout table for location information
University Hospital Zurich, Clinic and Policlinic of Internal Medicine Recruiting
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Layout table for investigator information
Principal Investigator: Pierre-Alexandre Krayenbuehl, MD University of Zurich

Layout table for additonal information
Responsible Party: University of Zurich Identifier: NCT01374776    
Other Study ID Numbers: Version number 2 fro
First Posted: June 16, 2011    Key Record Dates
Last Update Posted: December 13, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases